Last reviewed · How we verify
AZD 1222
AZD1222 is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19.
AZD1222 is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19. Used for COVID-19 prevention.
At a glance
| Generic name | AZD 1222 |
|---|---|
| Also known as | Vaxzevria®, Covishield®, ChadOx1 nCoV-19, ChAdOx1 nCoV-19 |
| Sponsor | University Medicine Greifswald |
| Drug class | Viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
AZD1222 uses a replication-deficient chimpanzee adenovirus vector to carry the gene encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular and humoral immune responses, generating antibodies and T-cell immunity against the spike protein. The vaccine does not contain the live virus and cannot cause COVID-19 infection.
Approved indications
- COVID-19 prevention
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection (PHASE1)
- EU Secondary Data Post-Authorisation Safety Study of AZD1222
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (PHASE4)
- NDV-HXP-S Vaccine Clinical Trial (COVIVAC) (PHASE2)
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (PHASE2, PHASE3)
- Immunogenicity of COVID-19 Vaccine on Heterologous Schedule (PHASE2)
- Study of AZD1222 for the Prevention of COVID-19 in Japan (PHASE1, PHASE2)
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD 1222 CI brief — competitive landscape report
- AZD 1222 updates RSS · CI watch RSS
- University Medicine Greifswald portfolio CI